MedTrace Logo

Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma

NCT04497779 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 95

Last updated 2025-12-05

No results posted yet for this study

Summary

Plasma from patients who have recovered from coronavirus disease 2019 (COVID-19) is referred to as COVID-19 convalescent plasma (CCP), and may contain antibodies against SARS-CoV-2, the virus responsible for COVID-19. CCP infusion is being evaluated as a therapeutic or prophylactic approach in COVID-19 patients. The goal of this study is to help develop a bank of convalescent plasma in California, especially in medically underserved communities particularly affected by the disease. In parallel, CCP administered to COVID-19 patients will be collected and analyzed to determine whether the antibody profile correlates with clinical outcome. The purpose of this non-therapeutic study is to learn more about the CCP antibody profile and the effect it may have in treating COVID-19 infection.

Conditions

  • Asymptomatic COVID-19 Infection Laboratory-Confirmed
  • Symptomatic COVID-19 Infection Laboratory-Confirmed

Interventions

PROCEDURE

Biospecimen Collection

Undergo collection of blood and/or nasopharyngeal swabs

OTHER

Diagnostic Laboratory Biomarker Analysis

Correlative studies

OTHER

Electronic Health Record Review

Donors and recipients have their medical records reviewed.

OTHER

Questionnaire Administration

Ancillary studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • California Institute for Regenerative Medicine (CIRM)

    collaborator OTHER

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • John Zaia · City of Hope Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-13
Primary Completion
2026-10-13
Completion
2026-10-13

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04497779 on ClinicalTrials.gov